alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

30,580 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 3,876–3,900 of 17,283 studies scoring 30–49 out of 100 (page 156 of 692) · 30,580 in the whole library · How the 0–100 score works

Download bibliography of the first 500 of these studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 16,054 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Usability and feasibility of INFORMA platform for computerized cognitive stimulation in mild cognitive impairment and early dementia: an 8-week multicenter study

✓ Peer-reviewed alzhub usefulness score 45 out of 100. Aging Clinical and Experimental Research 2026-03-13

Of 219 completing participants (mean age 73.5 years), the mean SUS score was 82.0 (95% CI: 80.3-83.8), with 84% exceeding the usability threshold (SUS score > 68). 5 key findings →

Participants: 241 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Combination of Intranasal insulin and oral semaglutide for cognition in older adults with metabolic syndrome at high dementia risk

✓ Peer-reviewed alzhub usefulness score 45 out of 100. Alzheimer s & Dementia 2025-12-01

Data collection began in March 2024. So far 562 people completed a pre-screening online questionnaire, with 190 passing pre-screening of whom 54% met eligibility criteria. 5 key findings →

Participants: 24 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Circulating immune cell phenotypes are associated with inflammatory biomarkers in dementia-free participants from the Framingham Heart Study Offspring cohort

✓ Peer-reviewed alzhub usefulness score 45 out of 100. Scientific Reports 2026-02-27

Inflammatory responses are characterized by the activation of immune cells, while inflammatory biomarkers intricately interact with the immune system. 4 key findings →

Design: cross-sectional Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Nonlinear Associations of Accelerometer-Based Sedentary Time With Cognitive Functions in the UK Biobank

✓ Peer-reviewed alzhub usefulness score 45 out of 100. The Journals of Gerontology Series B 2025-04-18

Except for the visual-spatial memory test, nonlinear approaches provided a better fit than linear methods to model the associations of sedentary time with other cognitive outcomes. 5 key findings →

Participants: 32,875 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Structural insights and milestones in TDP-43 research: A comprehensive review of its pathological and therapeutic advances

✓ Peer-reviewed alzhub usefulness score 45 out of 100. International Journal of Biological Macromolecules 2025-03-01

Transactive response (TAR) DNA-binding protein 43 (TDP-43) is a critical RNA/DNA-binding protein involved in various cellular processes, including RNA splicing, transcription regulation, and RNA stability. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

DCPS modulates TDP-43-linked neurodegeneration through P-body-mediated RNA decay

✓ Peer-reviewed alzhub usefulness score 45 out of 100. Neuron 2026-03-09

The proteinopathy of the RNA-binding protein TDP-43, characterized by nuclear clearance and cytoplasmic inclusion, is a hallmark of multiple neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and Alzheimer's disease (AD). 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Transcriptomic signature of frontotemporal lobar degeneration with TDP-43 type C pathology

✓ Peer-reviewed alzhub usefulness score 45 out of 100. Brain 2026-03-04

Our findings were compared to other published RNA sequencing data of tauopathies (Alzheimer's dementia, progressive supranuclear palsy and FTLD with MAPT), FTLD-TDP (subtypes A&B) and available proteomics of this cohort. 5 key findings →

Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Chitinase-3-like-1: a multifaceted player in neuroinflammation and degenerative pathologies with therapeutic implications

✓ Peer-reviewed alzhub usefulness score 45 out of 100. Molecular Neurodegeneration 2025-01-18

Chitinase-3-like-1 (CHI3L1) is an evolutionarily conserved protein involved in key biological processes, including tissue remodeling, angiogenesis, and neuroinflammation. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Neurofilament Biomarkers in Neurology: From Neuroinflammation to Neurodegeneration, Bridging Established and Novel Analytical Advances with Clinical Practice

✓ Peer-reviewed alzhub usefulness score 45 out of 100. International Journal of Molecular Sciences 2025-10-07

Neuroaxonal damage underlies permanent disability in various neurological conditions, both neuroautoimmune and neurodegenerative. 5 key findings →

Design: narrative review Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Neuroinflammation and blood–brain barrier dysfunction in cerebral small vessel disease: mechanisms, biomarkers, and therapeutic implications

✓ Peer-reviewed alzhub usefulness score 45 out of 100. European journal of medical research 2026-01-23

Cerebral small vessel disease (CSVD) is a chronic, progressive cerebrovascular disorder affecting small arteries, arterioles, venules, and capillaries, and is a leading contributor to stroke, vascular dementia, and cognitive impairment. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Ethanol consumption aggravates amyloid pathology and neuroinflammation in Alzheimer’s disease associated with inflammasome activation and ASC speck propagation

✓ Peer-reviewed alzhub usefulness score 45 out of 100. Journal of Neuroinflammation 2025-07-15

In this study, we show that repeated ethanol binges aggravate the amyloid pathology and plaque burden in the hippocampus of APP/PS1 mice. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Immune–proteo–metabolomic changes link to Aβ and tau pathology in Alzheimer disease

✓ Peer-reviewed alzhub usefulness score 45 out of 100. Alzheimer s & Dementia 2026-04-01

Thirteen differentially expressed CSF proteins in A+T+ individuals correlated positively with tryptophan metabolites and pyroglutamate, and negatively with regulatory T cells, isobutyrate, and dendritic cells. 4 key findings →

Participants: 19 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

[18F]Florzolotau PET for the Differential Diagnosis of Parkinsonism in Patients with Suspected 4-Repeat Tauopathies

✓ Peer-reviewed alzhub usefulness score 45 out of 100. Journal of Nuclear Medicine 2025-04-17

The 4R-like pattern was more prevalent and more strongly expressed (84.3%, mean score, 2.0 ± 1.1) in patients with a consensus diagnosis of PSP/CBD (joint diagnostic group of clinically likely 4R tauopathies) than in all other groups (11.6%, 0.26 ± 0.75, P < 0.0001). 5 key findings →

Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Plasma vesicle-associated membrane protein 2 and glial fibrillary acidic protein associate with synaptic density in older adults without dementia

✓ Peer-reviewed alzhub usefulness score 45 out of 100. Brain Communications 2025-01-01

The study population demonstrated limited PET-based amyloid-β and tau pathology, which did not associate with any of the investigated plasma biomarkers. 5 key findings →

Design: cross-sectional Participants: 49 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Retinal ganglion cell vulnerability to pathogenic tau in Alzheimer’s disease

✓ Peer-reviewed alzhub usefulness score 45 out of 100. Acta Neuropathologica Communications 2025-02-15

Using the RGC marker ribonucleic acid binding protein with multiple splicing (RBPMS) and Nissl staining, we found a 46–56% reduction in RBPMS + RGCs and Nissl + neurons in the ganglion cell layer (GCL) of MCI and AD retinas ( P < 0.05–0.001). 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 30,580 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 30,580 records, built mostly from automated pulls of Europe PMC (64.7% of the library) and OpenAlex (16.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,037 records (3.4% of the library) are not peer-reviewed — 964 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed    Where this research is being discussed: events